They were later FDA-approved for weight loss in 2014
And as indicated by the list above of upcoming trials, there may be several new indications in the near future
Recent Clinical Trial Results: EVOKE and EVOKE+ Two recent large-scale, double-blind, placebo-controlled, phase 3 trials, known as EVOKE and EVOKE+ evaluated oral semaglutide (Rybelsus) in patients with early Alzheimers disease [23]
(Top holdings, as of January 16, 2025, below): Source: Amplify ETFs The Roundhill GLP-1 & Weight Loss ETF (OZEM) is another ETF in this segment, also launched in May 2024
Service Members who are overweight with other risk factors or obese should work with their Department of War (DoW) medical officer or Primary Care Manager/Provider to determine if a GLP-1 medication is appropriate before starting these medications
A study found that over 18 months, people with type 2 diabetes who took 15 mg of tirzepatide (the active ingredient in Mounjaro) lost an average of 18% of their body weight, compared to 12.4% for those taking 2.4 mg of semaglutide